title: [Effective administration of recombinant granulocyte colony-stimulating factor to prevent granulocytopenia due to combination chemotherapy for testicular germ cell tumors].
abstract: A prospective randomized study on the administration of recombinant granulocyte colony stimulating factor (rG-CSF) was conducted on 15 patients with testicular germ cell tumors. The clinical stagings of all patients except one were minimal to moderate extent according to the Indiana University staging system. Combination chemotherapy using bleomycin, etoposide and cisplatinum (BEP) was performed as the initial treatment on the eligible patients. rG-CSF was administered by two different methods; 1) routine administration on the 6th day after BEP chemotherapy (group A), and 2) the same method, but after granulocytopenia of 1,500/mm3 had developed (group B). The administration of rG-CSF in group A significantly reduced the severity of leucocytopenia and also the incidence of stomatitis compared with group B. Although rG-CSF produced no significant side effects, the thrombocytopenia was prominent in the group A patients (not significant). BEP chemotherapy itself is an easily-tolerable and well established method for treating young adult patients. The method used in group B seems to be suitable in situations where thrombocytopenia and cost effectiveness.
authors.affiliation: Department of Urology, Hokkaido University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Nonomura
authors.forename: N
authors.initials: N
authors.lastname: Shinohara
authors.forename: Y
authors.initials: Y
authors.lastname: Shinno
authors.forename: T
authors.initials: T
authors.lastname: Seki
authors.forename: T
authors.initials: T
authors.lastname: Koyanagi
authors.forename: S
authors.initials: S
authors.lastname: Nagamori
authors.forename: J
authors.initials: J
authors.lastname: Fujieda
authors.forename: M
authors.initials: M
authors.lastname: Togashi
authors.forename: N
authors.initials: N
authors.lastname: Ohashi
authors.forename: N
authors.initials: N
authors.lastname: Abe
authors.forename: K
authors.initials: K
authors.lastname: Toyota
authors.forename: A
authors.initials: A
authors.lastname: Maru
authors.forename: T
authors.initials: T
authors.lastname: Gotoh
authors.forename: N
authors.initials: N
authors.lastname: Sakakibara
authors.forename: S
authors.initials: S
authors.lastname: Sakashita
authors.forename: M
authors.initials: M
authors.lastname: Kosugi
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
mesh_terms: D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D018237:Germinoma / Q000188:drug therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D011994:Recombinant Proteins; D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002945:Cisplatin